Maggie Stanislawski
Concepts (508)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 10 | 2026 | 769 | 2.530 |
Why?
| | Microbiota | 9 | 2026 | 725 | 1.770 |
Why?
| | Body Mass Index | 11 | 2026 | 2458 | 1.590 |
Why?
| | Obesity | 12 | 2026 | 3131 | 1.540 |
Why?
| | Weight Loss | 3 | 2026 | 858 | 1.180 |
Why?
| | Overweight | 2 | 2026 | 614 | 0.760 |
Why?
| | Life Style | 1 | 2025 | 496 | 0.720 |
Why?
| | Percutaneous Coronary Intervention | 11 | 2020 | 550 | 0.710 |
Why?
| | United States Department of Veterans Affairs | 14 | 2020 | 777 | 0.690 |
Why?
| | Behavior Therapy | 2 | 2021 | 291 | 0.680 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2025 | 2623 | 0.640 |
Why?
| | Fatty Liver | 2 | 2021 | 252 | 0.640 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 88 | 0.640 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 352 | 0.580 |
Why?
| | Feces | 5 | 2025 | 496 | 0.560 |
Why?
| | Biostatistics | 1 | 2018 | 19 | 0.550 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2025 | 2240 | 0.540 |
Why?
| | Coronary Artery Disease | 6 | 2023 | 751 | 0.510 |
Why?
| | Pacemaker, Artificial | 4 | 2020 | 127 | 0.500 |
Why?
| | Weight Gain | 2 | 2018 | 562 | 0.500 |
Why?
| | Multifactorial Inheritance | 4 | 2025 | 243 | 0.490 |
Why?
| | Bacteria | 3 | 2020 | 766 | 0.480 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 203 | 0.470 |
Why?
| | Insulin Resistance | 3 | 2024 | 1247 | 0.470 |
Why?
| | Risk Factors | 18 | 2025 | 10921 | 0.450 |
Why?
| | Phylogeny | 2 | 2018 | 924 | 0.440 |
Why?
| | Middle Aged | 34 | 2026 | 36619 | 0.440 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 265 | 0.430 |
Why?
| | Glucose Oxidase | 7 | 1994 | 25 | 0.430 |
Why?
| | Prosthesis-Related Infections | 4 | 2020 | 100 | 0.420 |
Why?
| | Female | 51 | 2026 | 79499 | 0.420 |
Why?
| | Pediatric Obesity | 2 | 2019 | 635 | 0.410 |
Why?
| | Male | 44 | 2026 | 73396 | 0.400 |
Why?
| | RNA, Ribosomal, 16S | 5 | 2018 | 507 | 0.400 |
Why?
| | Asthma | 1 | 2025 | 1800 | 0.400 |
Why?
| | Liver | 9 | 2020 | 1864 | 0.400 |
Why?
| | Humans | 64 | 2026 | 146342 | 0.400 |
Why?
| | Antibiotic Prophylaxis | 3 | 2020 | 140 | 0.400 |
Why?
| | Veterans Health | 4 | 2018 | 188 | 0.380 |
Why?
| | Phenotype | 6 | 2023 | 3206 | 0.380 |
Why?
| | Lactoperoxidase | 7 | 1994 | 7 | 0.360 |
Why?
| | Peroxidases | 5 | 1993 | 28 | 0.320 |
Why?
| | Coronary Artery Bypass | 4 | 2017 | 269 | 0.320 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 640 | 0.320 |
Why?
| | Aged | 27 | 2025 | 26432 | 0.310 |
Why?
| | Pregnancy | 7 | 2021 | 7230 | 0.310 |
Why?
| | Immunotoxins | 4 | 1990 | 51 | 0.300 |
Why?
| | Adult | 15 | 2026 | 41087 | 0.300 |
Why?
| | Dextrans | 5 | 1988 | 83 | 0.280 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2219 | 0.280 |
Why?
| | Veterans | 7 | 2018 | 1650 | 0.270 |
Why?
| | Immunoglobulin Idiotypes | 7 | 1988 | 28 | 0.270 |
Why?
| | Bifidobacterium | 2 | 2017 | 21 | 0.260 |
Why?
| | Genetic Predisposition to Disease | 4 | 2025 | 2488 | 0.260 |
Why?
| | Myocardial Infarction | 6 | 2018 | 1215 | 0.250 |
Why?
| | Cohort Studies | 7 | 2025 | 6077 | 0.250 |
Why?
| | Coronary Angiography | 7 | 2020 | 325 | 0.250 |
Why?
| | United States | 21 | 2025 | 16136 | 0.250 |
Why?
| | Genome-Wide Association Study | 5 | 2025 | 1537 | 0.230 |
Why?
| | Mississippi | 2 | 2025 | 34 | 0.220 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 234 | 0.220 |
Why?
| | Radial Artery | 2 | 2017 | 74 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 539 | 0.210 |
Why?
| | Time Factors | 11 | 2021 | 7109 | 0.210 |
Why?
| | Defibrillators, Implantable | 2 | 2020 | 393 | 0.210 |
Why?
| | Diet | 3 | 2023 | 1273 | 0.200 |
Why?
| | T-Lymphocytes | 8 | 1995 | 2012 | 0.200 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5899 | 0.200 |
Why?
| | Longevity | 1 | 2025 | 179 | 0.200 |
Why?
| | HIV-1 | 3 | 1995 | 913 | 0.200 |
Why?
| | Logistic Models | 3 | 2025 | 2126 | 0.190 |
Why?
| | Metabolomics | 2 | 2026 | 738 | 0.190 |
Why?
| | Risk Assessment | 4 | 2021 | 3712 | 0.190 |
Why?
| | Child | 6 | 2021 | 22693 | 0.190 |
Why?
| | Plasmacytoma | 8 | 1989 | 19 | 0.180 |
Why?
| | Registries | 3 | 2019 | 2400 | 0.180 |
Why?
| | Metagenomics | 1 | 2023 | 154 | 0.180 |
Why?
| | Age Factors | 2 | 2021 | 3347 | 0.180 |
Why?
| | Machine Learning | 2 | 2026 | 594 | 0.180 |
Why?
| | Norway | 2 | 2018 | 41 | 0.170 |
Why?
| | Patient Identification Systems | 2 | 2019 | 16 | 0.170 |
Why?
| | Mothers | 2 | 2018 | 772 | 0.170 |
Why?
| | Electronic Health Records | 2 | 2020 | 1210 | 0.170 |
Why?
| | Acute Kidney Injury | 2 | 2020 | 866 | 0.170 |
Why?
| | Proton Therapy | 1 | 2021 | 16 | 0.170 |
Why?
| | Diet, Reducing | 1 | 2021 | 90 | 0.170 |
Why?
| | Waist Circumference | 1 | 2021 | 142 | 0.170 |
Why?
| | Computational Biology | 1 | 2026 | 678 | 0.160 |
Why?
| | Incidence | 4 | 2021 | 2936 | 0.160 |
Why?
| | Adiposity | 1 | 2025 | 533 | 0.160 |
Why?
| | Gardening | 1 | 2020 | 13 | 0.160 |
Why?
| | Software | 1 | 2026 | 676 | 0.160 |
Why?
| | DNA, Bacterial | 2 | 2018 | 319 | 0.160 |
Why?
| | Prospective Studies | 4 | 2025 | 8123 | 0.150 |
Why?
| | Caloric Restriction | 1 | 2021 | 133 | 0.150 |
Why?
| | Mice, Inbred BALB C | 14 | 1989 | 1244 | 0.150 |
Why?
| | Fasting | 1 | 2021 | 280 | 0.150 |
Why?
| | Western World | 1 | 2019 | 7 | 0.150 |
Why?
| | Atherosclerosis | 1 | 2023 | 410 | 0.150 |
Why?
| | Weight Reduction Programs | 1 | 2021 | 140 | 0.150 |
Why?
| | Precision Medicine | 1 | 2023 | 462 | 0.140 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 19 | 0.140 |
Why?
| | Cardiac Catheterization | 3 | 2018 | 571 | 0.140 |
Why?
| | Fluid Therapy | 1 | 2020 | 154 | 0.140 |
Why?
| | Proportional Hazards Models | 6 | 2018 | 1331 | 0.140 |
Why?
| | Adolescent | 5 | 2021 | 22557 | 0.140 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.130 |
Why?
| | Drug Users | 1 | 2018 | 43 | 0.130 |
Why?
| | Vancomycin | 1 | 2018 | 96 | 0.130 |
Why?
| | Documentation | 1 | 2020 | 202 | 0.130 |
Why?
| | Genes, rRNA | 1 | 2017 | 38 | 0.130 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2017 | 892 | 0.130 |
Why?
| | Streptococcus | 1 | 2017 | 26 | 0.130 |
Why?
| | Atherectomy, Coronary | 1 | 2017 | 10 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2018 | 75 | 0.130 |
Why?
| | Perioperative Care | 1 | 2020 | 235 | 0.130 |
Why?
| | Coronary Stenosis | 1 | 2017 | 40 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1408 | 0.130 |
Why?
| | Behavior, Addictive | 1 | 2018 | 90 | 0.130 |
Why?
| | Antiviral Agents | 2 | 1994 | 779 | 0.130 |
Why?
| | History, 21st Century | 1 | 2018 | 224 | 0.130 |
Why?
| | Antibodies, Monoclonal | 10 | 2016 | 1512 | 0.130 |
Why?
| | Coronary Occlusion | 1 | 2017 | 20 | 0.130 |
Why?
| | Homeostasis | 1 | 2021 | 646 | 0.130 |
Why?
| | Antibodies | 8 | 1983 | 400 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 184 | 0.120 |
Why?
| | Data Collection | 1 | 2020 | 650 | 0.120 |
Why?
| | Contrast Media | 1 | 2020 | 493 | 0.120 |
Why?
| | Young Adult | 5 | 2021 | 14330 | 0.120 |
Why?
| | Psychological Trauma | 1 | 2017 | 58 | 0.120 |
Why?
| | Cocaine-Related Disorders | 1 | 2018 | 132 | 0.120 |
Why?
| | Hypertension | 1 | 2025 | 1272 | 0.120 |
Why?
| | Myeloma Proteins | 8 | 1984 | 13 | 0.120 |
Why?
| | Peroxidase | 2 | 1994 | 168 | 0.120 |
Why?
| | Population Surveillance | 1 | 2020 | 481 | 0.120 |
Why?
| | Binding Sites, Antibody | 6 | 1988 | 41 | 0.120 |
Why?
| | Program Evaluation | 3 | 2017 | 952 | 0.120 |
Why?
| | Antigens | 11 | 1979 | 350 | 0.120 |
Why?
| | Blood Transfusion | 2 | 2017 | 394 | 0.120 |
Why?
| | Mice, Inbred Strains | 5 | 1987 | 384 | 0.120 |
Why?
| | Immunoglobulin G | 11 | 1988 | 901 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2018 | 6460 | 0.120 |
Why?
| | Comorbidity | 2 | 2018 | 1665 | 0.120 |
Why?
| | Vascular Calcification | 1 | 2017 | 109 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 237 | 0.120 |
Why?
| | Glucose | 1 | 2021 | 1053 | 0.110 |
Why?
| | Mycoplasma | 1 | 1995 | 5 | 0.110 |
Why?
| | Femoral Artery | 1 | 2017 | 183 | 0.110 |
Why?
| | Mycoplasma Infections | 1 | 1995 | 17 | 0.110 |
Why?
| | Cross Reactions | 5 | 1988 | 130 | 0.110 |
Why?
| | Medication Errors | 1 | 2016 | 86 | 0.110 |
Why?
| | Antibody Specificity | 10 | 1989 | 181 | 0.110 |
Why?
| | Adipose Tissue | 1 | 2020 | 642 | 0.110 |
Why?
| | Research Report | 1 | 2016 | 89 | 0.110 |
Why?
| | Algorithms | 2 | 2020 | 1849 | 0.110 |
Why?
| | Treatment Outcome | 10 | 2019 | 11821 | 0.110 |
Why?
| | Blood Glucose | 2 | 2024 | 2360 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1101 | 0.110 |
Why?
| | Hemorrhage | 2 | 2017 | 825 | 0.110 |
Why?
| | Saphenous Vein | 1 | 2014 | 36 | 0.100 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 286 | 0.100 |
Why?
| | Prognosis | 2 | 2021 | 4351 | 0.100 |
Why?
| | Social Determinants of Health | 1 | 2018 | 317 | 0.100 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 88 | 0.100 |
Why?
| | Drug-Eluting Stents | 1 | 2014 | 88 | 0.100 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 305 | 0.100 |
Why?
| | Antimicrobial Stewardship | 1 | 2016 | 136 | 0.100 |
Why?
| | Hydrogen Peroxide | 1 | 1995 | 337 | 0.100 |
Why?
| | Infant | 2 | 2018 | 10114 | 0.100 |
Why?
| | Methionine Sulfoximine | 2 | 1990 | 2 | 0.100 |
Why?
| | Stents | 2 | 2014 | 554 | 0.100 |
Why?
| | Lymphocyte Depletion | 2 | 1990 | 135 | 0.100 |
Why?
| | Premature Birth | 1 | 2017 | 390 | 0.100 |
Why?
| | Carmustine | 2 | 1990 | 52 | 0.100 |
Why?
| | Patient Selection | 2 | 2016 | 728 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2017 | 461 | 0.090 |
Why?
| | Child, Preschool | 2 | 2018 | 11913 | 0.090 |
Why?
| | Aged, 80 and over | 6 | 2024 | 8391 | 0.090 |
Why?
| | Bone Marrow Transplantation | 2 | 1990 | 301 | 0.090 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 499 | 0.090 |
Why?
| | Chi-Square Distribution | 3 | 2018 | 517 | 0.090 |
Why?
| | Databases, Factual | 4 | 2019 | 1493 | 0.090 |
Why?
| | Retrospective Studies | 10 | 2020 | 17438 | 0.090 |
Why?
| | Immunoglobulin Allotypes | 3 | 1986 | 9 | 0.090 |
Why?
| | Nitrohydroxyiodophenylacetate | 2 | 1988 | 3 | 0.080 |
Why?
| | Antigens, Neoplasm | 4 | 1990 | 271 | 0.080 |
Why?
| | Rabbits | 15 | 1983 | 651 | 0.080 |
Why?
| | Coronary Disease | 1 | 2013 | 380 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1942 | 0.080 |
Why?
| | Sex Factors | 1 | 2017 | 2107 | 0.080 |
Why?
| | Bone Marrow | 2 | 1989 | 310 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 589 | 0.080 |
Why?
| | Hospitals, Veterans | 3 | 2018 | 256 | 0.080 |
Why?
| | Military Personnel | 1 | 2018 | 726 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2026 | 3017 | 0.080 |
Why?
| | Plasma Cells | 3 | 1976 | 80 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 733 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2786 | 0.080 |
Why?
| | Insulin | 1 | 2021 | 2525 | 0.080 |
Why?
| | Antibodies, Anti-Idiotypic | 3 | 1985 | 50 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1124 | 0.080 |
Why?
| | Prevalence | 4 | 2018 | 2861 | 0.070 |
Why?
| | Biomarkers | 1 | 2021 | 4340 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3926 | 0.070 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1988 | 21 | 0.070 |
Why?
| | Stroke | 1 | 2018 | 1287 | 0.070 |
Why?
| | Immunoglobulin Isotypes | 1 | 1988 | 36 | 0.070 |
Why?
| | Immune Sera | 11 | 1985 | 77 | 0.070 |
Why?
| | Glycoproteins | 1 | 1990 | 356 | 0.070 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 1986 | 83 | 0.070 |
Why?
| | Immunoglobulin M | 6 | 1983 | 284 | 0.070 |
Why?
| | Species Specificity | 2 | 1988 | 543 | 0.070 |
Why?
| | Mice | 30 | 1989 | 18297 | 0.070 |
Why?
| | Hospitalization | 2 | 2016 | 2475 | 0.070 |
Why?
| | Animals | 42 | 2021 | 38106 | 0.070 |
Why?
| | Nitrophenols | 1 | 1987 | 30 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4595 | 0.070 |
Why?
| | Adjuvants, Immunologic | 2 | 1988 | 245 | 0.070 |
Why?
| | Antibodies, Neoplasm | 2 | 1979 | 34 | 0.070 |
Why?
| | Cell Line | 6 | 1995 | 2814 | 0.070 |
Why?
| | Immunoglobulins | 7 | 1984 | 162 | 0.060 |
Why?
| | Receptors, Antigen, B-Cell | 5 | 1979 | 134 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 1986 | 70 | 0.060 |
Why?
| | Killer Cells, Natural | 2 | 1988 | 481 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2014 | 1107 | 0.060 |
Why?
| | Immunoglobulin Variable Region | 3 | 1983 | 78 | 0.060 |
Why?
| | Immunoelectrophoresis | 11 | 1976 | 13 | 0.060 |
Why?
| | Genes, MHC Class II | 2 | 1983 | 77 | 0.060 |
Why?
| | CpG Islands | 1 | 2025 | 175 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6073 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 970 | 0.050 |
Why?
| | Body Size | 1 | 2025 | 91 | 0.050 |
Why?
| | Anthropometry | 1 | 2025 | 204 | 0.050 |
Why?
| | Workflow | 1 | 2026 | 182 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1957 | 0.050 |
Why?
| | p-Azobenzenearsonate | 1 | 1983 | 5 | 0.050 |
Why?
| | B-Lymphocytes | 3 | 1979 | 887 | 0.050 |
Why?
| | Azo Compounds | 1 | 1983 | 30 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 496 | 0.050 |
Why?
| | Mice, Inbred A | 3 | 1988 | 47 | 0.050 |
Why?
| | Lymphocytes | 3 | 1979 | 379 | 0.050 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 1979 | 22 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 1983 | 210 | 0.040 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2021 | 18 | 0.040 |
Why?
| | Kinetics | 6 | 1989 | 1553 | 0.040 |
Why?
| | Adsorption | 4 | 1975 | 154 | 0.040 |
Why?
| | Diet Surveys | 1 | 2021 | 89 | 0.040 |
Why?
| | Binding, Competitive | 4 | 1983 | 185 | 0.040 |
Why?
| | Acyltransferases | 1 | 2021 | 78 | 0.040 |
Why?
| | Antibody Formation | 5 | 1987 | 290 | 0.040 |
Why?
| | Microsomes | 4 | 1975 | 33 | 0.040 |
Why?
| | Radiometry | 1 | 2021 | 56 | 0.040 |
Why?
| | Neoplasms, Experimental | 4 | 1979 | 163 | 0.040 |
Why?
| | Lipase | 1 | 2021 | 76 | 0.040 |
Why?
| | Immunoglobulin Fab Fragments | 3 | 2016 | 55 | 0.040 |
Why?
| | Lymph Nodes | 5 | 1985 | 511 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 712 | 0.040 |
Why?
| | Forehead | 1 | 2020 | 4 | 0.040 |
Why?
| | Protons | 1 | 2021 | 96 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 725 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 340 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 81 | 0.040 |
Why?
| | Buthionine Sulfoximine | 2 | 1990 | 9 | 0.040 |
Why?
| | Phantoms, Imaging | 1 | 2021 | 160 | 0.040 |
Why?
| | Patient Readmission | 2 | 2017 | 778 | 0.040 |
Why?
| | Mouth | 1 | 2020 | 84 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 48 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1990 | 1998 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 853 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2020 | 120 | 0.040 |
Why?
| | Gene-Environment Interaction | 1 | 2021 | 190 | 0.040 |
Why?
| | HIV Infections | 1 | 1995 | 3215 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 731 | 0.040 |
Why?
| | Immunoglobulin mu-Chains | 1 | 1979 | 8 | 0.040 |
Why?
| | Multiple Myeloma | 3 | 1984 | 310 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 139 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.040 |
Why?
| | Immunoglobulin Light Chains | 1 | 1979 | 52 | 0.040 |
Why?
| | Child Behavior | 1 | 2021 | 234 | 0.040 |
Why?
| | Oceania | 1 | 2018 | 5 | 0.040 |
Why?
| | Carrier Proteins | 1 | 1983 | 728 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2019 | 69 | 0.040 |
Why?
| | Drug Synergism | 2 | 1990 | 354 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 857 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 104 | 0.040 |
Why?
| | Antigens, Surface | 1 | 1979 | 155 | 0.040 |
Why?
| | Blood Pressure | 1 | 2025 | 1765 | 0.030 |
Why?
| | Cattle | 1 | 2021 | 940 | 0.030 |
Why?
| | Teratoma | 1 | 1979 | 121 | 0.030 |
Why?
| | Antigens, CD | 2 | 1993 | 560 | 0.030 |
Why?
| | Skin | 1 | 2023 | 701 | 0.030 |
Why?
| | Genes, Regulator | 1 | 1978 | 34 | 0.030 |
Why?
| | Peptides | 4 | 2016 | 992 | 0.030 |
Why?
| | Quality Improvement | 2 | 2018 | 1354 | 0.030 |
Why?
| | Mice, Inbred C57BL | 9 | 1988 | 6034 | 0.030 |
Why?
| | Mice, Inbred C3H | 4 | 1988 | 252 | 0.030 |
Why?
| | Erythrocytes | 3 | 1989 | 750 | 0.030 |
Why?
| | Glutathione | 2 | 1990 | 369 | 0.030 |
Why?
| | North America | 1 | 2018 | 300 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3647 | 0.030 |
Why?
| | Echocardiography, Stress | 1 | 2017 | 29 | 0.030 |
Why?
| | Europe | 1 | 2018 | 421 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2020 | 314 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1203 | 0.030 |
Why?
| | Punctures | 1 | 2017 | 40 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2020 | 385 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 1989 | 77 | 0.030 |
Why?
| | Transfusion Reaction | 1 | 2017 | 61 | 0.030 |
Why?
| | Fibrosarcoma | 1 | 1976 | 22 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 870 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2017 | 183 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 2 | 1990 | 432 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 349 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 88 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 745 | 0.030 |
Why?
| | Drug Labeling | 1 | 2016 | 37 | 0.030 |
Why?
| | Adolescent Behavior | 1 | 2021 | 486 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2016 | 60 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 253 | 0.030 |
Why?
| | Vasodilator Agents | 1 | 2017 | 326 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 1135 | 0.030 |
Why?
| | Risk-Taking | 1 | 2018 | 321 | 0.030 |
Why?
| | Health Behavior | 1 | 2021 | 802 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 6 | 1993 | 326 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 503 | 0.030 |
Why?
| | Fluorescence | 1 | 1995 | 160 | 0.030 |
Why?
| | Cell Survival | 2 | 1990 | 1105 | 0.030 |
Why?
| | Device Removal | 1 | 2016 | 149 | 0.030 |
Why?
| | Immunodiffusion | 7 | 1974 | 13 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2021 | 1130 | 0.030 |
Why?
| | Bioprosthesis | 1 | 2014 | 39 | 0.030 |
Why?
| | Phytohemagglutinins | 1 | 1994 | 29 | 0.030 |
Why?
| | HIV Core Protein p24 | 1 | 1994 | 32 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1077 | 0.030 |
Why?
| | Angina, Unstable | 1 | 2014 | 83 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1994 | 162 | 0.030 |
Why?
| | Immune Tolerance | 3 | 1993 | 386 | 0.030 |
Why?
| | Catalase | 1 | 1994 | 133 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2092 | 0.020 |
Why?
| | Metals | 1 | 2014 | 137 | 0.020 |
Why?
| | Health Promotion | 1 | 2020 | 786 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1543 | 0.020 |
Why?
| | Mortality | 1 | 2016 | 375 | 0.020 |
Why?
| | Polystyrenes | 1 | 1993 | 38 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1993 | 70 | 0.020 |
Why?
| | Inflammation | 1 | 2024 | 2919 | 0.020 |
Why?
| | Lymphokines | 1 | 1993 | 127 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 2018 | 609 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1993 | 106 | 0.020 |
Why?
| | Fibronectins | 1 | 1993 | 136 | 0.020 |
Why?
| | Patient Safety | 1 | 2016 | 352 | 0.020 |
Why?
| | CD4 Antigens | 1 | 1993 | 136 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1591 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 846 | 0.020 |
Why?
| | Immunization, Passive | 2 | 1989 | 90 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2113 | 0.020 |
Why?
| | Mental Health | 1 | 2018 | 779 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1888 | 0.020 |
Why?
| | Heparin | 1 | 1993 | 247 | 0.020 |
Why?
| | Epitopes | 4 | 1979 | 479 | 0.020 |
Why?
| | Acrylamides | 1 | 1972 | 74 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 801 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 2 | 1989 | 224 | 0.020 |
Why?
| | Blood Proteins | 1 | 1973 | 239 | 0.020 |
Why?
| | CD52 Antigen | 1 | 1990 | 3 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1827 | 0.020 |
Why?
| | Thymus Neoplasms | 1 | 1990 | 30 | 0.020 |
Why?
| | Thymoma | 1 | 1990 | 38 | 0.020 |
Why?
| | Mice, Inbred DBA | 2 | 1988 | 186 | 0.020 |
Why?
| | Isoelectric Focusing | 2 | 1988 | 30 | 0.020 |
Why?
| | Virus Replication | 1 | 1993 | 526 | 0.020 |
Why?
| | Proteins | 2 | 1993 | 1022 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 415 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1990 | 434 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2867 | 0.020 |
Why?
| | Dinitrophenols | 1 | 1988 | 6 | 0.020 |
Why?
| | Trinitrobenzenes | 1 | 1988 | 14 | 0.020 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 8 | 0.020 |
Why?
| | Rats, Nude | 1 | 1988 | 24 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 1990 | 882 | 0.020 |
Why?
| | Esterases | 3 | 1968 | 9 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 1969 | 230 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 3 | 1975 | 50 | 0.020 |
Why?
| | Oxidative Stress | 1 | 1995 | 1369 | 0.020 |
Why?
| | Hybridomas | 2 | 1993 | 233 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 1989 | 328 | 0.020 |
Why?
| | Lymphoma | 1 | 1990 | 251 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1989 | 1041 | 0.020 |
Why?
| | Medicare | 1 | 2013 | 920 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 1993 | 2092 | 0.020 |
Why?
| | Sheep | 4 | 1981 | 870 | 0.020 |
Why?
| | Rats | 7 | 1988 | 5586 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2020 | 3034 | 0.020 |
Why?
| | Immunotherapy | 2 | 1989 | 671 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1988 | 315 | 0.020 |
Why?
| | Isoelectric Point | 1 | 1986 | 21 | 0.020 |
Why?
| | Electrophoresis | 4 | 1968 | 31 | 0.020 |
Why?
| | Chromium Radioisotopes | 1 | 1986 | 4 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1989 | 585 | 0.010 |
Why?
| | Heart Failure | 1 | 2020 | 2329 | 0.010 |
Why?
| | Abortion, Veterinary | 1 | 1986 | 2 | 0.010 |
Why?
| | Methods | 2 | 1979 | 68 | 0.010 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1969 | 370 | 0.010 |
Why?
| | Fetal Resorption | 1 | 1985 | 2 | 0.010 |
Why?
| | Fetal Death | 1 | 1985 | 59 | 0.010 |
Why?
| | Neoplasm Transplantation | 4 | 1984 | 238 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5439 | 0.010 |
Why?
| | Precipitin Tests | 2 | 1975 | 90 | 0.010 |
Why?
| | Cell Nucleus | 4 | 1968 | 584 | 0.010 |
Why?
| | Immunoglobulin Constant Regions | 1 | 1983 | 7 | 0.010 |
Why?
| | H-2 Antigens | 2 | 1986 | 111 | 0.010 |
Why?
| | Cells, Cultured | 2 | 1990 | 4118 | 0.010 |
Why?
| | Acetates | 1 | 1963 | 78 | 0.010 |
Why?
| | Phenylalanine | 1 | 1963 | 69 | 0.010 |
Why?
| | Interferon Type I | 1 | 1984 | 147 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 1969 | 776 | 0.010 |
Why?
| | Chromatography | 2 | 1973 | 27 | 0.010 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1983 | 127 | 0.010 |
Why?
| | Perfusion | 1 | 1963 | 255 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1981 | 47 | 0.010 |
Why?
| | Clone Cells | 2 | 1979 | 259 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1981 | 54 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1993 | 49 | 0.010 |
Why?
| | Research | 1 | 1963 | 421 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 1979 | 170 | 0.010 |
Why?
| | Papain | 1 | 1979 | 3 | 0.010 |
Why?
| | Thymus Gland | 1 | 1979 | 310 | 0.010 |
Why?
| | Genes | 1 | 1978 | 215 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1978 | 271 | 0.010 |
Why?
| | Immunosorbent Techniques | 1 | 1976 | 16 | 0.010 |
Why?
| | Spleen | 3 | 1979 | 503 | 0.010 |
Why?
| | Sarcoma, Experimental | 1 | 1976 | 6 | 0.010 |
Why?
| | Mitochondria | 1 | 1963 | 997 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1976 | 26 | 0.010 |
Why?
| | Vaccination | 1 | 1985 | 1449 | 0.010 |
Why?
| | Glutaral | 1 | 1975 | 14 | 0.010 |
Why?
| | Antigens, Heterophile | 1 | 1975 | 4 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1976 | 148 | 0.010 |
Why?
| | Immunoassay | 1 | 1976 | 108 | 0.010 |
Why?
| | Cytoplasm | 1 | 1976 | 253 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1976 | 345 | 0.010 |
Why?
| | Cell Differentiation | 2 | 1974 | 1982 | 0.010 |
Why?
| | Antibody-Producing Cells | 1 | 1974 | 30 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1974 | 131 | 0.010 |
Why?
| | Chloroform | 1 | 1973 | 2 | 0.010 |
Why?
| | Globulins | 1 | 1973 | 2 | 0.010 |
Why?
| | Immunoglobulin Fragments | 1 | 1973 | 11 | 0.010 |
Why?
| | Thermolysin | 1 | 1993 | 4 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1983 | 2599 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 1976 | 449 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1973 | 6 | 0.010 |
Why?
| | Absorption | 1 | 1993 | 60 | 0.010 |
Why?
| | CD57 Antigens | 1 | 1993 | 18 | 0.010 |
Why?
| | Chick Embryo | 1 | 1973 | 132 | 0.010 |
Why?
| | Solubility | 1 | 1973 | 240 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 1993 | 197 | 0.010 |
Why?
| | Microspheres | 1 | 1993 | 142 | 0.010 |
Why?
| | Hydrolysis | 1 | 1993 | 195 | 0.010 |
Why?
| | Chickens | 1 | 1973 | 169 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1993 | 139 | 0.010 |
Why?
| | Immunochemistry | 1 | 1972 | 12 | 0.010 |
Why?
| | Immunologic Techniques | 1 | 1972 | 36 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1972 | 161 | 0.010 |
Why?
| | Cell Membrane | 1 | 1975 | 701 | 0.010 |
Why?
| | Muramidase | 1 | 1972 | 66 | 0.010 |
Why?
| | Animals, Newborn | 1 | 1974 | 888 | 0.010 |
Why?
| | Leukocytes | 1 | 1973 | 301 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1972 | 144 | 0.010 |
Why?
| | Cholinesterases | 2 | 1968 | 9 | 0.010 |
Why?
| | Aldehydes | 1 | 1972 | 140 | 0.010 |
Why?
| | Deoxyribonucleases | 2 | 1968 | 24 | 0.010 |
Why?
| | L-Lactate Dehydrogenase | 2 | 1968 | 113 | 0.010 |
Why?
| | Lipoproteins | 1 | 1971 | 165 | 0.000 |
Why?
| | Blotting, Western | 1 | 1993 | 1177 | 0.000 |
Why?
| | Protein Conformation | 1 | 1993 | 916 | 0.000 |
Why?
| | Endoplasmic Reticulum | 1 | 1971 | 268 | 0.000 |
Why?
| | Ethanol | 1 | 1973 | 630 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1993 | 2838 | 0.000 |
Why?
| | Protein Binding | 1 | 1993 | 2244 | 0.000 |
Why?
| | Liver Diseases | 1 | 1969 | 304 | 0.000 |
Why?
| | Enzymes | 1 | 1966 | 60 | 0.000 |
Why?
| | Fetal Viability | 1 | 1985 | 3 | 0.000 |
Why?
| | Genetic Variation | 1 | 1970 | 996 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1985 | 56 | 0.000 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1986 | 180 | 0.000 |
Why?
| | Pronase | 1 | 1981 | 4 | 0.000 |
Why?
| | Rosette Formation | 1 | 1981 | 14 | 0.000 |
Why?
| | Trypsin | 1 | 1981 | 73 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1985 | 677 | 0.000 |
Why?
| | Contact Inhibition | 2 | 1970 | 5 | 0.000 |
Why?
| | Culture Techniques | 2 | 1970 | 65 | 0.000 |
Why?
| | Lymphocyte Activation | 1 | 1985 | 1137 | 0.000 |
Why?
| | Ascitic Fluid | 1 | 1979 | 15 | 0.000 |
Why?
| | Microscopy, Electron | 2 | 1970 | 384 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 365 | 0.000 |
Why?
| | Epithelium | 2 | 1970 | 295 | 0.000 |
Why?
| | beta-Galactosidase | 1 | 1979 | 73 | 0.000 |
Why?
| | Cell Cycle | 1 | 1981 | 595 | 0.000 |
Why?
| | Placenta | 1 | 1985 | 794 | 0.000 |
Why?
| | Fibroblasts | 2 | 1970 | 1034 | 0.000 |
Why?
| | Neuraminic Acids | 1 | 1972 | 1 | 0.000 |
Why?
| | Neuraminidase | 1 | 1972 | 27 | 0.000 |
Why?
| | Densitometry | 1 | 1972 | 36 | 0.000 |
Why?
| | Vibrio cholerae | 1 | 1972 | 14 | 0.000 |
Why?
| | Ultracentrifugation | 1 | 1972 | 49 | 0.000 |
Why?
| | Microsomes, Liver | 1 | 1972 | 85 | 0.000 |
Why?
| | Leukemia Virus, Murine | 1 | 1970 | 17 | 0.000 |
Why?
| | Intestines | 1 | 1972 | 351 | 0.000 |
Why?
|
|
Stanislawski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|